Browse by author
Lookup NU author(s): Judith Unterlass,
Professor Nicola Curtin
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Warburg and coworkers' observation of altered glucose metabolism in tumours has been neglected for several decades, which, in part, was because of an initial misinterpretation of the basis of their finding. Following the realisation that genetic alterations are often linked to metabolism, and that the tumour micro-environment imposes different demands on cancer cells, has led to a reinvestigation of cancer metabolism in recent years. Increasing our understanding of the drivers and consequences of the Warburg effect in cancer and beyond will help to identify new therapeutic strategies as well as to identify new prognostic and therapeutic biomarkers. Here we discuss the initial findings of Warburg and coworkers regarding cancer cell glucose metabolism, how these studies came into focus again in recent years following the discovery of metabolic oncogenes, and the therapeutic potential that lies within targeting the altered metabolic phenotype in cancer. In addition, another essential nutrient in cancer metabolism, glutamine, will be discussed.
Author(s): Unterlass JE, Curtin NJ
Publication type: Article
Publication status: Published
Journal: Expert Reviews in Molecular Medicine
Online publication date: 27/09/2019
Acceptance date: 28/05/2019
ISSN (electronic): 1462-3994
Publisher: Cambridge University Press
PubMed id: 31558177
Altmetrics provided by Altmetric